On May 1, 2024, IMAC Holdings, Inc., based in Franklin, Tennessee announced that it had acquired the assets of Theralink Technologies, Inc. as part of a Settlement and Release Agreement between the two companies. The acquisition was made in settlement of Theralink’s default on certain outstanding debt. With IMAC Holdings now in possession of Theralink’s assets, the previously planned merger between the two companies is no longer necessary.

IMAC Holdings has decided to formally withdraw the Registration Statement on Form S-4 that was related to the now-terminated Merger Agreement. The company believes that this new settlement arrangement will allow Theralink’s advancements in breast cancer diagnostics to continue to progress under the IMAC Holdings umbrella.

Jeff Ervin, the Chief Executive Officer of IMAC Holdings stated that the settlement will enable Theralink’s services to be commercialized more efficiently and effectively. The company is now focusing on stabilizing operations and transitioning key employees to further capitalize on the success of Theralink’s proteomic analysis and precision medicine expertise.

IMAC Holdings is a clinical research and commercialization company that specializes in medical advancements and care within the oncology, neurological, and orthopedic fields. For more information about the company visit www.imacholdings.com or contact jeff@imacholdings